Financial Information

HORIBA, Ltd. June, 2020

(This material was prepared for the 2020Q1 financial results briefing performed on the 25th Jun., 2020)

© 2020 HORIBA, Ltd. All rights reserved.

2019 Results

2020 Forecasts

Progress of MLMAP2023

- Shareholder Return
- Other Topics

Financial Data

Corporate Profile

2019 Results

2020 Forecasts

Progress of MLMAP2023

- Shareholder Return
- Other Topics

• Financial Data

• Corporate Profile

Review of 2019

| External Events | The rise of protectionism (the US-China trade conflict, the deteriorating Japan-South Korea relationship) BREXIT Slowdown in capital spending on semiconductors The accelerating automotive electrification trend and tighter emission regulations globally |
|--------------------|---|
| Internal Events | Formulation of the Mid-Long Term Management Plan "MLMAP2023" Continual enhancement of R&D bases on a global scale Aggressive launch of new products Selected as a "Nadeshiko Brand" and for the "Health & Productivity Stock Selection Program" by METI and the Tokyo Stock Exchange |

Summary of 2019 Results

| Year-on year decrease in sales and profit due to slowdown of the semiconductor segment | | | | | | |
|--|---|--|--|--|--|--|
| ופס | Year-on-year decrease in sales and profit of the Semiconductor segment due to impacts of the market | | | | | |
| PAL | P&L Due to a change in geographical sales mix and other factors, decline in profitability of the Automotive segment though the sales increased | | | | | |
| B/S | Total assets were ¥315.1bn, increase ¥37.7bn, mainly due to increase in cash caused by issuing corporate debts | | | | | |
| | Equity ratio: 54.3% (-3.9%) (compared to the end of Dec. 2018) | | | | | |
| | Operating CF: Cash in ¥26.6bn due to operating profit | | | | | |
| CF | Investing CF: Cash out ¥12.3bn due to acquisition of tangible Free CF: +14.2bn | | | | | |
| 20 HORIBA Ltd. All rights reserved | Financial CF: Cash in ¥19.2bn due to issue of corporate debts | | | | | |

2019 Results

(Billions of Yen)

| | 2018 | | 2019 | | |
|--|---------|-----------------------------|---------|------------|-----------------------------------|
| | Results | Forecast (as of Nov. 11) | Results | vs 2018 | VS Forecast (as of Nov. 11) |
| Sales | 210.5 | 207.0 | 200.2 | -10.3 | -6.7 |
| Operating Profit | 28.8 | 23.0 | 20.9 | -7.9 | -2.0 |
| O.P.% | 13.7% | 11.1% | 10.4% | -3.3p | -0.7p |
| Ordinary Profit | 28.3 | 22.5 | 20.5 | -7.7 | -1.9 |
| Net Income attributable to Owners of Parent | 22.3 | 16.0 | 15.4 | -6.8 | -0.5 |
| USD/JPY | 110.44 | 110.00 | 109.03 | -1.41 | -0.97 |
| EUR/JPY | 130.35 | 122.00 | 122.03 | -8.32 | +0.03 |

2019 Results by Segment

(Billions of Yen)

| | Sales | | | | | Ор | erating p | rofit | | |
|---------------|---------|-----------------------------|---------------|------------|-----------------------------------|---------|-----------------------------|---------|------------|-----------------------------------|
| | 2018 | | 2019 |) | | 2018 | | 2019 | 9 | |
| ★:Record-high | Results | Forecast (as of Nov. 11) | Results | vs 2018 | VS Forecast (as of Nov. 11) | Results | Forecast (as of Nov. 11) | Results | vs 2018 | VS Forecast (as of Nov. 11) |
| Auto | 79.6 | 83.0 | * 81.0 | +1.3 | -1.9 | 7.7 | 7.0 | 6.4 | -1.2 | -0.5 |
| P&E | 19.3 | 20.0 | * 19.5 | +0.1 | -0.4 | 2.0 | 2.0 | 1.6 | -0.3 | -0.3 |
| Medical | 26.0 | 26.0 | 25.3 | -0.6 | -0.6 | 1.8 | 1.5 | 1.3 | -0.5 | -0.1 |
| Semi | 57.7 | 50.0 | 47.1 | -10.5 | -2.8 | 17.0 | 12.0 | 10.7 | -6.3 | -1.2 |
| Scientific | 27.7 | 28.0 | 27.1 | -0.5 | -0.8 | 0.2 | 0.5 | 0.7 | +0.5 | +0.2 |
| Total | 210.5 | 207.0 | 200.2 | -10.3 | -6.7 | 28.8 | 23.0 | 20.9 | -7.9 | -2.0 |

2019 Results

2020 Forecasts

Progress of MLMAP2023

Shareholder Return

Other Topics

• Financial Data

• Corporate Profile

Background of the Announcement of

Earnings Forecasts and Dividend Forecasts

- 14th Feb. Disclosed Earnings Forecasts and
 - **Dividend Forecasts**
 - 16th Apr. Withdrew Earnings Forecasts and
 - Dividend Forecasts
 - (First Half / Full-year / Dividend)
- 20th May
 9th Jun.
 Re-disclosed Earnings Forecasts and
 - Re-disclosed Earnings Forecasts and
 Oividend Forecasts
- 11th Aug. Announcement of the First Half of Financial Results

- In response to the relaxation of restriction of the public's
 movements in various countries
 and other factors, compiled data
 regarding potential impacts and
 forecasts of each Group
 company
- Disclose forecasts based on the currently-available information and projections

2020 Forecasts

(Billions of Yen)

| | 2019 | 2020 | | | | | | |
|---|---------|-----------------|------------|-------------|-----------|-------|---------|--|
| | Results | Forecast | Forecast | | | | vs 2019 | |
| | | (as of Feb. 14) | First Half | Second Half | Full year | Yen | % | |
| Sales | 200.2 | 215.0 | 84.0 | 103.0 | 187.0 | -13.2 | -7% | |
| Operating Profit | 20.9 | 25.0 | 5.5 | 9.5 | 15.0 | -5.9 | -28% | |
| 0.P. % | 10.4% | 11.6% | 6.5% | 9.2% | 8.0% | -2.4p | | |
| Ordinary Profit | 20.5 | 24.5 | 5.5 | 9.0 | 14.5 | -6.0 | -29% | |
| Neto Income attributable to Owners of Parent | 15.4 | 17.5 | 4.0 | 6.5 | 10.5 | -4.9 | -32% | |
| Not Profit por Sharo (von) | 367 | 414 | | | 248 | -118 | | |
| Net Profit per Share (yen) | | | | | | | | |
| ROE | 9.3% | 9.9% | | | 6.1% | -3.2p | | |

(Billions of Yen)

2020 Forecasts by Segments

| | | 2019 | | 20 | 20 | |
|-----------|------------|---------|--------------------|-----------|-------|------|
| | | | | Forecast | vs 2 | 019 |
| | | Results | (as of Fec. 14) | Full year | Yen | % |
| | Auto | 81.0 | 85.0 | 68.0 | -13.0 | -16% |
| | P&E | 19.5 | 21.5 | 17.5 | -2.0 | -10% |
| Sales | Medical | 25.3 | 27.0 | 23.0 | -2.3 | -9% |
| Sales | Semi | 47.1 | 52.5 | 52.5 | 5.3 | 11% |
| | Scientific | 27.1 | 29.0 | 26.0 | -1.1 | -4% |
| | Total | 200.2 | 215.0 | 187.0 | -13.2 | -7% |
| | Auto | 6.4 | 7.5 | 0.5 | -5.9 | -92% |
| | P&E | 1.6 | 1.5 | 0.5 | -1.1 | -71% |
| Operating | Medical | 1.3 | 1.5 | 0.2 | -1.1 | -85% |
| Profit | Semi | 10.7 | 13.5 | 13.5 | 2.7 | 26% |
| | Scientific | 0.7 | 1.0 | 0.3 | -0.4 | -59% |
| | Total | 20.9 | 25.0 | 15.0 | -5.9 | -28% |

[Topics by segments]

<Auto, Process & Environment, Scientific>

- Product shipment and acceptance may be delayed because of measures to restrict the movements of people and goods by various countries and regions.
- Sales are expected to decline owing to impacts caused by the downturn in the automobile industry, energy industry and other markets.

<Medical>

Sales are projected to decrease due to a decrease in the number of tests performed at hospitals as a result of a decrease in the number of general patients because of the spread of COVID-19.


<Semi>

- Recovery in capital expenditure by semiconductor manufacturers
- Sales to semiconductor production equipment manufacturers are expected to remain firm.
- An increase in demand for semiconductors are expected owing to the expansion of telework, digital business, and others

Market Assumptions by Regions and HORIBA Group's Status

| Market Assumption | | HORIBA Group's Status | | | |
|-------------------|--|-----------------------|------------|-----------------|--|
| in respons | in response to the spread of COVID-19 | | Production | Promotion/Sales | |
| Japan | Recovery of sales are expected along with full- scale recovery of economic activities after the state of emergency was lifted. | | | | |
| China/Asia | Recovery of sales are expected as the situation in East Asian such as China was settle down a bit earlier. Keep an eye on the prospects of US-China trade friction. | | | | |
| Americas | Economic activities were resumed and are promoted, but heightening concerns about the situation. | | | | |
| Europe | Economic activities were resumed after the state of emergency was lifted. | | | | |

Cash Balance



Reduction of external borrowing through intra-group lending
Recent issuer rating: R&I "A"(Oct. 2019), JCR "A+" (Oct. 2019)

*Cash...Cash and bank deposit at end of period



Approach to Capital Investments and R&D

Capital investment

- Continue strategic investment from a long-term perspective
 - Continue large-scale capital investment such as construction of new facility in China; scrutinizing the schedule
- Scrutinize renewal investment and others and implement from the most urgent
- R&D investment
 - Continue investment, looking ahead of demand recovery period
 - Consider priority of investment

Forecasts has not been determined

 \checkmark To be announced when the second quarter financial results are announced

■2019 Results 2020 Forecasts Progress of MLMAP2023 Shareholder Return Other Topics Financial Data Corporate Profile

Priority Measures of MLMAP2023



MLMAP2023 Slogan "ONE STAGE AHEAD"

1. Market Oriented Business

 To develop analysis and measurement solutions, utilizing HORIBA's core technologies, in the leading three business fields of the mega trend

2. Solution Provider Beyond Life Cycle Management

 To support customers' core businesses from all aspects – from product introduction to replacement

3. HORIBA Core Values "The Next Stage of Super Dream Team"

- To enhance the organizational structure that fosters resilient human resources, which are the driving force of all businesses
 - BlackJack Project/Stained Glass Project/HORIBA Premium Value

Market Oriented Business

Energy & Environment




Global increase in demand for electrified vehicles


Enhance the field of evaluation of fuel cell and power-train systems



Open the test facility for evaluation of batteries for electrified vehicles "CELL 0"



Useful in evaluating electrified vehicles and fuel cells



- Enable connection from CELL0 up to CELL3
- Total evaluation system "Test in the Loop"
- Offer value-added measurement solutions

Establish a production system that responds to demand

HORIBA FuelCon's new facility

Magdeburg in Germany (architectural rendering) Construction to be completed at the end of 2021 Total cost: approx. 3.5 billion yen

> Expand production capacity Shorten lead times with strategic facilities Become a center of excellence for electrification business


Market Oriented Business

HORIBA


Energy & Environment

Growing Needs for Environmental Measures





Respond to globally expanding environmental regulations



Bio & Healthcare

Medical: Expand and Maintain Production Bases



HORIBA

Japan

Renovate the production line at Aso Plant, HORIBA STEC

Reinforce adaptation to the global standard



France

Purchase of the land adjacent to HORIBA ABX

- Establish a base for production, storage and logistics
- Respond to an increase in production under the partnership agreement with Siemens Healthcare Diagnostics Inc.



Emerging countries

Prepare for the expanding Medical business

India, China

- Strengthen the reagent supply system
- ✓ Enhance local production



Strengthen the structure globally to expand business in the focus market


Market Oriented Business

Bio & Healthcare





HORIBA



2020 Masao Horiba Awards



【Theme】 Research in the field of life sciences, notably state-of-the-art optical/spectroscopic measurement technologies Support technology development in the field of cutting-edge drug discovery and medicine manufacture Solution Provider Beyond Life Cycle Management



To Change to a Solution-proposal Style Business

Always with You Support customers in all ways



In the same premises as HORIBA HQ, Kyoto Construction to be completed in Nov. 2020 Total cost: approx. 3.8 billion yen

Building a new HQ for HORIBA TECHNO SERVICE

✓ Integrate functions and enhance abilities to gather/transmit information
 ✓ Expand the analysis lab, the maintenance facility and the training space

| MLMA | P2023 | | | | | |
|---|-----------------------------------|--|--|--|--|--|
| Maintenance services using operating data | Consulting using measurement data | | | | | |
| Integrate equipment sales with high-value-added support | | | | | | |

Aim to create a new business to provide data and solutions based on analysis technologies

Start construction of a new facility in China



Integrate strengths of all businesses and R&D/production/service functions



Jiading, Shanghai Construction to be completed in April 2021 Total cost: approx. 9.0 billion yen

Automotive testing labs

✓ Install battery/fuel cell test systems, chassis dynamo, and drive test systems

✓ Enable tests that combine vehicles/real machines and simulation

Scientific analysis application center

- ✓ Profit from being based in China's new energy development area
- ✓ Collaborate with academia and companies in application development

Manufacturing

- Enhance local engineering and supply capacity for gas and water monitoring systems
- Establish a production system to supply the semiconductor market in China

Technical center

 Provide services according to the product life cycle, from installation to aftersales service

Aim to further expand business in the Chinese market



A "Super Dream Team" to Embody "Joy and Fun"

Activities to create new value and realize a strong HORIBA

BlackJack Project

Basis for multi-product low-volume manufacturing and a global business



BLACK JACK

Expand across the entire group

Close contact between the front-line and top management

[BlackJack Project]

HORIBA's unique operational improvement initiative began in 1997 with the objective of changing the awareness and activities of employees

Aim to be a truly flat organization

Stained Glass Project

Promote diversity as a management strategy

Encourage change in awareness and action to achieve both "job satisfaction" and a "comfortable working environment"

Think about employees' healthcare from the management perspective

Issued the "Physical and Mental Health Promotion Declaration" by top management and carried out various activities



[Example] Promote health management activities through meals

Improve productivity and enhance competitiveness

Highly evaluated from the ESG investment perspective

2019 Results

2020 Forecasts

Progress of MLMAP2023

Shareholder Return

Other Topics

• Financial Data

• Corporate Profile


Shareholder Return

Basic policy

- Dividend payment + Share buyback = 30% of Consolidated net profit to be targeted
- Remaining earnings are retained internally for strategic investment (i.e. facilities, M&A)

Dividends per share and Share buybacks

- 2018 Results: 145yen [Interim 50yen/Year-end 95yen (inc. Commemorative dividend 20 yen]
- 2019 Results: 130yen [Interim 50yen/Year-end 80yen]
- 2020 Forecasts: 75yen [Interim 30yen/Year-end 45yen]



2019 Results

2020 Forecasts

Progress of MLMAP2023

Shareholder Return

Other Topics

• Financial Data

• Corporate Profile

Expand Core Technologies and Contribute to Society

HORIBA Jobin Ybon IBH received the Business Innovation Award from the Institute of Physics in the UK



- Award theme: Development of FLIMERA, fluorescence lifetime microscope camera
- Joint development project members: Prof. Henderson, University of Edinburgh (back row, third from left), Prof. Burch, University of Strathclyde (front row, third from left), and others

Institute of Physics Business Innovation Award

Awarding companies which realize successful innovation utilizing physics



Fluorescence lifetime microscope camera, FLIMERA

 Applicable technology in observation of living cells in the bio and life-science field Montajir Rahman, HORIBA Instruments (US), received the SAE/InterRegs Standards & Regulations Award 2020



- Montajir Rahman (center) obtained a doctorate degree from a university in Japan
- Awarded for his work and involvement in numerous regulations and industry standards related to emissions reduction

SAE/InterRegs Standards & Regulations Award

Rewards and encourages engineers' participation in standards and regulations

- SAE (Society of Automotive Engineers): A US non-profit organization with members who are experts in the mobility field
- InterRegs: A UK organization which collects information related to vehicle safety and emission regulations and provides such information online

Awarded Nadeshiko Brands and Health & Productivity HORIBA Stock Selection Program by METI and Tokyo Stock Exchange

Activities aimed at realizing a better working environment highly evaluated from the stock market Selected for two consecutive years following 2019



Evaluated our activities based on the "Health promotion activities of mind and body", the policy declared by the management



Evaluated the engagement based on our Diversity promotion activities "HORIBA Stained Glass Project"

2019 Results

2020 Forecasts

Progress of MLMAP2023

Shareholder Return

Other Topics

Financial Data

• Corporate Profile

2020 Jan.-Mar. Results

(Billions of Yen)

Decreased in sales and profits due to a decline in sales all business segments except the semiconductor segment

| | 2019 | 2020 | vs 2019 | |
|--|-------------------------|-------------------------|-----------|----|
| | 1Q Results (Jan-Mar) | 1Q Results (Jan-Mar) | Changes % |) |
| Sales | 45.3 | 44.9 | -0.3 -1 | ۱% |
| Operating Profit | 4.4 | 3.8 | -0.5 -12 | 2% |
| O.P.% | 9.8% | 8.7% | -1.1p | |
| Ordinary Profit | 4.3 | 3.9 | -0.3 -9 | 9% |
| Net income attributable to Owners or Parent | 2.5 | 2.2 | -0.2 -12 | ۱% |
| | | | | |
| USD/JPY | 110.22 | 108.86 | -1.36 | |
| EUR/JPY | 125.16 | 120.08 | -5.08 | |

2020 Jan.-Mar. Results by Segments

(Billions of Yen)

| | Sales | | | | |
|------------|-------------------------|-------------------------|---------|------|--|
| | 2019 | 2020 | | | |
| | 1Q Results (Jan-Mar) | 1Q Results (Jan-Mar) | vs 2019 | % | |
| Auto | 16.2 | 14.8 | -1.3 | -8% | |
| P&E | 4.7 | 4.5 | -0.1 | -4% | |
| Medical | 6.3 | 5.7 | -0.5 | -9% | |
| Semi | 11.5 | 13.8 | 2.2 | +20% | |
| Scientific | 6.4 | 5.9 | -0.4 | -8% | |
| Total | 45.3 | 44.9 | -0.3 | -1% | |

| | Operating Profit | | | | | |
|------------|-------------------------|-------------------------|---------|------|--|--|
| | 2019 | 2020 | | | | |
| | 1Q Results (Jan-Mar) | 1Q Results (Jan-Mar) | vs 2019 | % | | |
| Auto | 0.9 | 0.3 | -0.5 | -64% | | |
| P&E | 0.4 | 0.2 | -0.2 | -47% | | |
| Medical | 0.2 | 0.1 | -0.0 | -25% | | |
| Semi | 2.7 | 3.2 | 0.4 | +18% | | |
| Scientific | 0.0 | -0.0 | -0.1 | - | | |
| Total | 4.4 | 3.8 | -0.5 | -12% | | |

<Auto>

- Affected by stagnation of corporate activities owing to the spread of COVID-19
 > EMS: Decline in sales in Europe and Americas while increased in Japan
 > MCT: Sales decrease owing to stagnation of projects mainly in China
 < P&E>
- Affected by stagnation of corporate activities owing to the spread of COVID-19
 Sales of stack gas analyzers and water quality analyzers declined in Asia
 <Medical>
- Decline in sales of blood cell testing instruments in the Americas, Asia and Japan

<Semi>

- Increase in sales in response to a gradual recovery of semiconductor manufactures' capital expenditure
- <Scientific>
- Sluggish R&D investment by companies and others due to the spread of COVID-19
 - > Sales of Raman Spectrometers and others declined in Japan and Asia

Impact of Fluctuation in Foreign exchange

(Billions of Yen)


Exchange rate impact (2020 Jan.-Mar. results)

| 2020 JanMar. results | vs 2019 |
|------------------------------|---------|
| Decrease Sales | - 0.68 |
| Decrease Cost of Goods Sales | + 0.39 |
| Decrease Expense | + 0.21 |
| Impact to Operatinf Profit | - 0.07 |

| (Yen) | 2019 JanMar. | 2020 JanMar. | Deiff. |
|-------|--------------|--------------|--------|
| USD | 110.22 | 108.86 | - 1.36 |
| EUR | 125.16 | 120.08 | - 5.08 |

(Billions of Yen)

Operating Profit Analysis (vs 2019)



Capital Investment, Depreciation, R&D

(Billions of Yen)

Increase in capital expenditures due to enhancement of business sites Forecasts will be disclosed as soon as they become available.

| | 2019 | 2019 | 2020 |
|--------------------|---------|-------------------------|-------------------------|
| | Results | 1Q Results (JanMar.) | 1Q Results (JanMar.) |
| Capital Investment | 12.8 | 2.3 | 3.4 |
| Depreciation | 8.7 | 2.0 | 2.3 |
| R&D | 16.2 | 4.0 | 4.1 |
| (To Net Sales) | 8.1% | 8.9% | 9.1% |

2019 Results

2020 Forecasts

Progress of MLMAP2023

Shareholder Return


Other Topics

Financial Data

Corporate Profile


Business Segments






Expanding in New Domains and Moving onto a New Stage

Global Network



HORIBA's Steady Growth



HORIBA MIRA Ltd. HORIBA BIWAKO E-HARBOR


HORIBA MIRA Ltd.

Providing Engineering Service with World Leading Mobility Development Capability and R&D Location with Dedicated Facilities and Proving Ground

| Business Offering | 1. Vehicle development engineering |
|--------------------------|------------------------------------|
| | 2. Test engineering |
| | 3. MIRA Technology Park |
| | (Providing Unique R&D Location) |
| Established | 1946 |
| Head office | Nuneaton, Warwickshire, UK |
| Major locations | U.K., China, and India |



MIRA Technology Park





HORIBA BIWAKO E-HARBOR


- Consolidating development, design, and production operations of gas measurement equipment at a single location
- Doubling of production capability and shortening delivery time to one-third by using a new production methodology
- Comprehensive engineering services from sales to development, production, and maintenance in the Automotive testing laboratory
 - Profitability improvement of exhaust gas analyzers
 - Presenting cutting edge automotive development technology





Total investment: 10.0 billion yen, Location: Otsu City, Shiga Prefecture, Full operation : May 2016

HORIBA BIWAKO E-HARBOR















Thank you



2020 Forecasts

| Status of each segment following the spread of COVID-19 | | |
|---|--|---|
| Auto | The reduction in R&D investment by automotive manufacturers, given a decline in automobile sales, will have an impact. | |
| | Product shipment and delivery may be delayed because of measures to restrict the public's movements by various countries and regions. | |
| P&E | | It is highly possible that the introduction of environmental regulations will slow down, especially in emerging countries, and sales may decline. |
| Medical | Continuing production in order to keep providing medical equipment and reagents even in areas where the public's movements have been restricted. | |
| | Trends of medical policy vary by country and region, which makes it difficult to project the demand outlook. | |
| Semi | An increase in demand for semiconductors is expected due to rapid expansion of telecommuting and digital business. | |
| | Bookings and sales to semiconductor production equipment manufacturers are expected to remain firm along with a gradual recovery of capital expenditures of semiconductor manufacturers. | |
| Scientific | | Sales is likely to decrease due to sluggish R&D investments by companies |

Response to the spread of COVID-19

HORIBA Group's response and status

(As of May 20th, 2020)

- The production/distribution situation varies depending on the country/region and business.
- While service and maintenance are impacted due to restriction of people's movement, HORIBA continues business activities as much as possible.
- Procurement is generally on schedule but with some delay.
 - [Japan] There is no significant impact.
 - [Europe] In France the medical base is in operation and the scientific base has restarted. In Germany and the UK the bases are in operation as much as possible.
 - [U.S.] Continuing production but some bases are closed.
 - [China] Normal operation resumed in late March.
- Following government policies of each country, many group companies in Japan and overseas have adopted teleworking as appropriate case by case.